

Dacomitinib Monotherapy

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement Status
Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations	C34	00565a	CDS - 01/11/2019 ⁱ

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Dacomitinib is administered once daily until disease progression or unacceptable toxicity.

Drug	Dose	Route	Cycle
Dacomitinib	45mg	PO	Continuous
Dacomitinib can be taken with or without food			
In the case of a missed dose or vomiting occurs a replacement dose should not be taken. Normal dosing should be resumed at the next scheduled dose.			

ELIGIBILITY:

- Indications as above
- EGFR activating mutation status as demonstrated by a validated test method
- ECOG 0-1
- Adequate renal, hepatic, and hematologic function

CAUTION:

Use with caution in patients with

- History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease

EXCLUSIONS:

- Known hypersensitivity to dacomitinib or its excipients

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist

TESTS:

Baseline tests:

- Assessment of EGFR mutation status by an accurate and valid test
- Baseline staging scans
- FBC, renal, liver and bone profile

NCCP Regimen: Dacomitinib Monotherapy	Published: 12/07/2019 Review: 12/07/2021	Version number: 2
Tumour Group: lung NCCP Regimen Code: 00565	ISMO Contributor: Prof Maccon Keane	Page 1 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Regular tests:

- FBC, renal, liver and bone profile

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Table 1 shows the dose reduction levels recommended for dacomitinib
- Any dose modification should be discussed with a Consultant.

Table 1: Dacomitinib recommended dose reduction levels

Dose level	Dacomitinib
Recommended starting dose	45 mg
First dose reduction	30 mg
Second dose reduction	15 mg

Renal and Hepatic Impairment:

Table 2: Recommended dose modification of dacomitinib in renal and hepatic impairment

Severity	Renal Impairment	Hepatic Impairment
Mild - moderate	No dose adjustment is recommended	No dose adjustment is recommended
Severe	The recommended dose of dacomitinib has not been established for patients with severe renal impairment	The recommended dose of dacomitinib has not been established for patients with severe hepatic impairment (Child-Pugh class C)

NCCP Regimen: Dacomitinib Monotherapy	Published: 12/07/2019 Review: 12/07/2021	Version number: 2
Tumour Group: lung NCCP Regimen Code: 00565	ISMO Contributor: Prof Maccon Keane	Page 2 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Management of adverse events:

Table 3: Recommended dose modification of dacomitinib for Adverse Events

Adverse reactions	Severity *	Dose modification
Interstitial lung disease (ILD/ Pneumonitis)	Any Grade	Withhold during ILD/Pneumonitis diagnostic evaluation Permanently discontinue if ILD/Pneumonitis is confirmed
Diarrhoea	Grade 1	No dose modification required. Initiate appropriate medical treatment
	Grade 2	Withhold if not improved to ≤ Grade 1 within 24 hours despite treatment; upon recovery resume at the same dose level or consider reduced dose level
	Grade ≥3	Withhold until recovery ≤Grade 1; then resume at a reduced dose level
Skin reactions	Grade 1	None**
	Grade 2	Withhold if not improved to ≤ Grade 1 within 72 hours despite treatment: upon recovery resume at the same dose level or consider reduced dose level
	Grade ≥3	Withhold until recovery ≤Grade 1; then resume at a reduced dose level
Other	Grade 1-2	No dose modification required
	Grade ≥3	Withhold until recovery ≤Grade 2; then resume a reduced dose level

* National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4

** Refer to local policy for the prevention and treatment of EGFR-inhibitor adverse skin reactions

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: Minimal to low (**Refer to local policy**).

PREMEDICATIONS: Not required

OTHER SUPPORTIVE CARE:

- Medication may be required for management of diarrhoea (**Refer to local policy**)
- See local skin care policy for the prevention and treatment of EGFR-inhibitor adverse skin reactions

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.

- **Interstitial Lung Disease (ILD):** Severe and fatal ILD/pneumonitis has been reported in patients treated with dacomitinib. Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis. Withhold treatment and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Permanently discontinue if ILD is confirmed
- **Diarrhoea:** Diarrhoea, including severe diarrhoea, has been very commonly reported during treatment with dacomitinib. Proactive management of diarrhoea should start at the first sign of

NCCP Regimen: Dacomitinib Monotherapy	Published: 12/07/2019 Review: 12/07/2021	Version number: 2
Tumour Group: lung NCCP Regimen Code: 00565	ISMO Contributor: Prof Maccon Keane	Page 3 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

diarrhoea especially within the first 2 weeks of starting dacomitinib, including adequate hydration combined with anti-diarrhoeal medicinal products and continued until loose bowel movements cease for 12 hours. Anti-diarrhoeal medicinal products (e.g., loperamide) should be used and, if necessary, escalated to the highest recommended approved dose. Patients may require dosing interruption and/or dose reduction of therapy with dacomitinib. Patients should maintain adequate oral hydration and patients who become dehydrated may require administration of intravenous fluids and electrolytes

- Dermatologic Adverse Reactions:** Rash erythematous and exfoliative skin reactions have been reported in patients treated with dacomitinib. See local skin care policy for the prevention and treatment of EGFR-inhibitor adverse skin reactions.
 Rash, erythematous and exfoliative skin conditions may occur or worsen in areas exposed to the sun. Advise patients to use protective clothing and sunscreen before exposure to the sun. Patients may require dosing interruption and/or dose reduction of therapy with dacomitinib. (See table 4 for management).
- Hepatotoxicity and increased transaminases:** There have been cases of hepatotoxicity reported in patients treated with dacomitinib in clinical studies therefore, periodic liver function testing is recommended. In patients who develop severe elevations in transaminases while taking dacomitinib, treatment should be interrupted

DRUG INTERACTIONS:

- The concomitant use of proton pump inhibitors should be avoided with dacomitinib. Locally-acting antacids or H2 receptor antagonists can be used as an alternative. If using a H2-receptor antagonist, administer dacomitinib at least 6 hours before or 10 hours after taking an H2-receptor antagonist
- The concomitant use of CYP2D6 substrates with dacomitinib increases the concentration of drugs that are CYP2D6 substrates which may increase the risk of toxicities of these drugs. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities
- Current drug interaction databases should be consulted for more information

ATC CODE:

Dacomitinib: L01XE47

REFERENCES:

- Wu Prof et al. Dacomitinib versus gefitinib as first-line treatment for patients with *EGFR* -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncology*, 2017-11-01, 18:11: 1454-1466
- Vizimpro® Summary of Product characteristics accessed June 2019 available at https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf

Version	Date	Amendment	Approved By
1	10/07/2019		Prof Maccon Keane
2	31/10/2019	Reimbursement status updated	NCCP

NCCP Regimen: Dacomitinib Monotherapy	Published: 12/07/2019 Review: 12/07/2021	Version number: 2
Tumour Group: lung NCCP Regimen Code: 00565	ISMO Contributor: Prof Maccon Keane	Page 4 of 5
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens		

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

ⁱ ODMS – Oncology Drug Management System

CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

Further details on the Cancer Drug Management Programme is available at;

<http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/>

NCCP Regimen: Dacomitinib Monotherapy	Published: 12/07/2019 Review: 12/07/2021	Version number: 2
Tumour Group: lung NCCP Regimen Code: 00565	ISMO Contributor: Prof Maccon Keane	Page 5 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		